Charles River Laboratories International, Inc. (CRL)
NYSE: CRL · Real-Time Price · USD
155.00
+2.25 (1.47%)
At close: Aug 13, 2025, 4:00 PM
155.00
0.00 (0.00%)
After-hours: Aug 13, 2025, 7:00 PM EDT
CRL Revenue
Charles River Laboratories International had revenue of $1.03B in the quarter ending June 28, 2025, with 0.59% growth. This brings the company's revenue in the last twelve months to $4.03B, down -1.21% year-over-year. In the year 2024, Charles River Laboratories International had annual revenue of $4.05B, down -1.92%.
Revenue (ttm)
$4.03B
Revenue Growth
-1.21%
P/S Ratio
1.95
Revenue / Employee
$200,429
Employees
20,100
Market Cap
7.63B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 28, 2024 | 4.05B | -79.42M | -1.92% |
Dec 30, 2023 | 4.13B | 153.35M | 3.86% |
Dec 31, 2022 | 3.98B | 435.90M | 12.31% |
Dec 25, 2021 | 3.54B | 616.23M | 21.08% |
Dec 26, 2020 | 2.92B | 302.71M | 11.55% |
Dec 28, 2019 | Pro | Pro | Pro |
Dec 29, 2018 | Pro | Pro | Pro |
Dec 30, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 26, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
CRL News
- 7 days ago - Charles River Laboratories International, Inc. (CRL) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 7 days ago - Charles River Sees Limited Impact From NIH Cuts, Tariffs, Drug Pricing - Benzinga
- 7 days ago - Charles River: Margin Fears Outweigh Solid Q2 - Seeking Alpha
- 7 days ago - Charles River raises profit forecast on growing demand for drug development services - Reuters
- 7 days ago - Charles River Laboratories Announces Second-Quarter 2025 Results - Business Wire
- 22 days ago - Charles River Joins Elly's Team to Drive Rare Disease Gene Therapy Development - Business Wire
- 4 weeks ago - Charles River Laboratories Schedules Second-Quarter 2025 Earnings Release and Conference Call - Business Wire
- 2 months ago - Charles River Announces Endosafe® Cartridge Recycling Program, Strengthening Sustainability Commitment - Business Wire